Jason S Lewis Selected Research

6- amino- 8- ((6- iodo- 1,3- benzodioxol- 5- yl)thio)- N- (1- methylethyl)- 9H-purine-9-propanamine

10/2020	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
3/2016	Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.
9/2011	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.
1/2010	Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jason S Lewis Research Topics

Disease

164	Neoplasms (Cancer) 03/2022 - 01/2002
29	Breast Neoplasms (Breast Cancer) 11/2021 - 07/2005
28	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 09/2005
20	Hypoxia (Hypoxemia) 06/2020 - 03/2002
12	Neoplasm Metastasis (Metastasis) 03/2022 - 04/2009
12	Pancreatic Neoplasms (Pancreatic Cancer) 03/2022 - 12/2015
9	Colorectal Neoplasms (Colorectal Cancer) 11/2020 - 08/2013
7	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 08/2013
7	Glioma (Gliomas) 01/2021 - 02/2007
6	Adenocarcinoma 10/2021 - 11/2013
5	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2020 - 03/2013
4	Stomach Neoplasms (Stomach Cancer) 01/2022 - 06/2013
4	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2013
4	Brain Neoplasms (Brain Tumor) 01/2021 - 01/2013
4	Carcinoma (Carcinomatosis) 10/2018 - 02/2008
4	Melanoma (Melanoma, Malignant) 05/2009 - 04/2005
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2017
3	Acidosis 01/2022 - 01/2017
3	Lymphoma (Lymphomas) 01/2018 - 02/2016
3	Uterine Cervical Neoplasms (Cancer of the Cervix) 07/2008 - 04/2003
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 01/2020
2	Inflammation (Inflammations) 10/2021 - 10/2019
2	Lobular Carcinoma 01/2021 - 09/2016
2	Ductal Carcinoma 01/2021 - 09/2016
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 05/2014

Drug/Important Bio-Agent (IBA)

29	AntigensIBA 10/2021 - 10/2011
23	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2008
20	Immunoconjugates (Immunoconjugate)IBA 03/2022 - 08/2013
18	AntibodiesIBA 01/2022 - 08/2013
18	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2005
16	Radioisotopes (Radionuclides)IBA 01/2021 - 07/2002
12	RadiopharmaceuticalsIBA 01/2021 - 12/2006
12	human ERBB2 proteinIBA 01/2021 - 06/2013
11	Trastuzumab (Herceptin)FDA Link 01/2022 - 01/2010
11	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 04/2012
11	copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)IBA 02/2010 - 11/2002
10	ErbB Receptors (EGF Receptor)IBA 01/2022 - 06/2013
10	Pharmaceutical PreparationsIBA 01/2022 - 10/2006
9	LigandsIBA 01/2022 - 03/2002
9	Peptides (Polypeptides)IBA 01/2021 - 04/2005
8	Monoclonal AntibodiesIBA 03/2022 - 03/2009
8	Chelating AgentsIBA 01/2020 - 07/2002
8	CopperIBA 03/2015 - 03/2002
7	Biological ProductsIBA 09/2021 - 04/2007
7	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 12/2020 - 07/2002
6	Somatostatin Receptors (Somatostatin Receptor)IBA 12/2020 - 07/2002
6	Glucose (Dextrose)FDA LinkGeneric 03/2020 - 09/2003
6	AndrogensIBA 11/2016 - 09/2005
5	Immunoglobulin G (IgG)IBA 01/2022 - 03/2009
5	procaine isothiocyanate (PRIT)IBA 01/2020 - 01/2017
4	Pentetic Acid (DTPA)FDA LinkGeneric 01/2022 - 07/2002
4	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2022 - 01/2016
4	Phosphotransferases (Kinase)IBA 01/2021 - 01/2019
4	Liposomes (Liposome)IBA 01/2021 - 03/2013
4	CarbohydratesIBA 10/2020 - 03/2016
4	6- amino- 8- ((6- iodo- 1,3- benzodioxol- 5- yl)thio)- N- (1- methylethyl)- 9H-purine-9-propanamineIBA 10/2020 - 01/2010
4	fluoromisonidazoleIBA 06/2020 - 04/2005
4	AcidsIBA 05/2020 - 10/2010
4	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 05/2009
4	zirconium-89-trastuzumabIBA 01/2018 - 06/2013
4	alpha-MSHIBA 05/2009 - 04/2005
3	CholesterolIBA 01/2022 - 01/2016
3	Panitumumab (Vectibix)FDA Link 01/2022 - 12/2020
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2021 - 03/2014
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 06/2013
3	Cetuximab (Erbitux)FDA Link 01/2021 - 03/2014
3	Lovastatin (Mevacor)FDA LinkGeneric 12/2020 - 12/2018
3	PolymersIBA 06/2020 - 01/2018
3	Deferoxamine (Desferal)FDA LinkGeneric 01/2020 - 10/2010
3	Zirconium-89IBA 01/2020 - 01/2016
3	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 12/2019 - 07/2002
3	Hormones (Hormone)IBA 01/2019 - 01/2013
3	Transferrin (beta 2 Transferrin)IBA 01/2018 - 01/2013
3	Immunoglobulin FragmentsIBA 07/2017 - 03/2009
3	Estrogen ReceptorsIBA 04/2015 - 05/2009
3	Deoxyglucose (2 Deoxy D glucose)IBA 08/2014 - 09/2003
3	Fatty Acid Synthases (Fatty Acid Synthase)IBA 01/2013 - 02/2008
3	ThiosemicarbazonesIBA 12/2006 - 03/2002
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 12/2020
2	Caveolin 1IBA 01/2022 - 12/2018
2	N- (2- amino- 3- (4- isothiocyanatophenyl)propyl)cyclohexane- 1,2- diamine- N,N',N',N'',N''- pentaacetic acidIBA 01/2022 - 05/2009
2	Immune Checkpoint InhibitorsIBA 12/2021 - 10/2021
2	salicylhydroxamic acid (SHAM)IBA 11/2021 - 01/2020
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2021 - 01/2020
2	onartuzumabIBA 01/2021 - 01/2020
2	GoldIBA 01/2021 - 01/2019
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 11/2016
2	ProteomeIBA 01/2021 - 09/2011
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 01/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 11/2016
2	omburtamab I-131IBA 12/2020 - 12/2019

Therapy/Procedure

73	Therapeutics 03/2022 - 01/2002
22	Radiotherapy 10/2021 - 04/2003
12	Radioimmunotherapy 01/2022 - 10/2010
9	Drug Therapy (Chemotherapy) 01/2021 - 04/2003
8	Castration 01/2022 - 04/2012
5	Precision Medicine 03/2022 - 11/2019
3	Ligation 01/2019 - 02/2015
2	Immunotherapy 03/2021 - 01/2020
2	Aftercare (After-Treatment) 01/2021 - 02/2008